WO2010103140A3 - Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna - Google Patents

Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna Download PDF

Info

Publication number
WO2010103140A3
WO2010103140A3 PCT/ES2010/000097 ES2010000097W WO2010103140A3 WO 2010103140 A3 WO2010103140 A3 WO 2010103140A3 ES 2010000097 W ES2010000097 W ES 2010000097W WO 2010103140 A3 WO2010103140 A3 WO 2010103140A3
Authority
WO
WIPO (PCT)
Prior art keywords
faeces
breast milk
characterisation
strains
isolation
Prior art date
Application number
PCT/ES2010/000097
Other languages
English (en)
French (fr)
Other versions
WO2010103140A2 (es
Inventor
José María VIEITES FERNÁNDEZ
Sergio MUÑOZ QUEZADA
Inmaculada Llamas Company
José MALDONADO LOZANO
Fernando Romero Braquehais
Antonio Francisco SUÁREZ GARCÍA
Ángel GIL HERNÁNDEZ
Original Assignee
Hero España, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hero España, S.A. filed Critical Hero España, S.A.
Priority to ES10750390.6T priority Critical patent/ES2532095T3/es
Priority to PL10750390T priority patent/PL2407532T3/pl
Priority to US13/255,842 priority patent/US8637297B2/en
Priority to CN201080020442.2A priority patent/CN102421889B/zh
Priority to RU2011138363/10A priority patent/RU2551315C2/ru
Priority to EP10750390.6A priority patent/EP2407532B1/en
Priority to DK10750390.6T priority patent/DK2407532T3/en
Publication of WO2010103140A2 publication Critical patent/WO2010103140A2/es
Publication of WO2010103140A3 publication Critical patent/WO2010103140A3/es
Priority to US13/841,604 priority patent/US20130280790A1/en
Priority to US13/841,135 priority patent/US20130280789A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/519—Breve
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pediatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención se refiere a microorganismos probióticos aislados de heces de niños alimentados exclusivamente con leche materna. Dichos microorganismos, dadas sus propiedades probióticas que confieren efectos beneficiosos en la salud de quienes los ingieren, son de aplicación en la industria alimenticia o farmacéutica, especialmente para su uso en fórmulas lácteas para la infancia. Dichos microorganismos consisten en Lactobacillus rhamnosus HERO 22A (CNCM 1-4036), Lactobacillus paracasei HERO 7 (CNCM 1-4034) y Bifidobacterium breve HERO 15B (CNCM I-4035).
PCT/ES2010/000097 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna WO2010103140A2 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES10750390.6T ES2532095T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificacion y caracterizacion de cepas con actividad probiotica a partir de heces de lactantes alimentados exclusivamente con leche materna
PL10750390T PL2407532T3 (pl) 2009-03-10 2010-03-09 Izolowanie, identyfikacja i charakteryzowanie szczepów o działaniu probiotycznym pochodzących z kału niemowląt karmionych wyłącznie mlekiem matki
US13/255,842 US8637297B2 (en) 2009-03-10 2010-03-09 Isolation, identification and characterization of strains with probiotic activity, from faeces of infants fed exclusively with breast milk
CN201080020442.2A CN102421889B (zh) 2009-03-10 2010-03-09 来自完全以母乳喂养的婴儿粪便的具有益生活性的菌株的分离、鉴定和表征
RU2011138363/10A RU2551315C2 (ru) 2009-03-10 2010-03-09 Выделение, идентификация и характеристика штаммов с пробиотической активностью, выделенных из фекалий детей, вскармливаемых исключительно материнским молоком
EP10750390.6A EP2407532B1 (en) 2009-03-10 2010-03-09 Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk
DK10750390.6T DK2407532T3 (en) 2009-03-10 2010-03-09 Isolation, identification and characterization of strains with probiotic activity from the faeces of infants exclusively fed with human breast milk
US13/841,604 US20130280790A1 (en) 2009-03-10 2013-03-15 Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk
US13/841,135 US20130280789A1 (en) 2009-03-10 2013-03-15 Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/ES2009/000130 WO2010103132A1 (es) 2009-03-10 2009-03-10 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
ESPCT/ES09/000130 2009-03-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/841,135 Division US20130280789A1 (en) 2009-03-10 2013-03-15 Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk
US13/841,604 Division US20130280790A1 (en) 2009-03-10 2013-03-15 Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk

Publications (2)

Publication Number Publication Date
WO2010103140A2 WO2010103140A2 (es) 2010-09-16
WO2010103140A3 true WO2010103140A3 (es) 2010-11-04

Family

ID=42727821

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/ES2009/000130 WO2010103132A1 (es) 2009-03-10 2009-03-10 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
PCT/ES2010/000097 WO2010103140A2 (es) 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/ES2009/000130 WO2010103132A1 (es) 2009-03-10 2009-03-10 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna

Country Status (8)

Country Link
US (3) US8637297B2 (es)
EP (3) EP2407532B1 (es)
CN (3) CN104232544B (es)
DK (3) DK2407532T3 (es)
ES (3) ES2532095T3 (es)
PL (3) PL2848681T4 (es)
RU (1) RU2551315C2 (es)
WO (2) WO2010103132A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453591C1 (ru) * 2011-04-21 2012-06-20 Общество с ограниченной ответственностью "Бифилюкс" Штамм lactobacillus rhamnosus, используемый для получения продукции, содержащей лактобактерии

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2008231467A1 (en) * 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic Bifidobacterium strains
EP2600877A4 (en) 2010-08-04 2014-05-07 Borody Thomas J COMPOSITIONS FOR FLORAL TRANSPLANTATION OF FECAL MATERIALS AND METHODS OF MAKING AND USING SAME, AND DEVICES FOR THEIR ADMINISTRATION
JP2014507481A (ja) 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 結腸微生物相移植のための組成物及び方法
KR101228035B1 (ko) * 2011-06-29 2013-01-30 주식회사 쎌바이오텍 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
ES2675309T3 (es) * 2012-11-12 2018-07-10 Compagnie Gervais Danone Uso de una cepa de Lactobacillus rhamnosus para reducir la ganancia de peso y/o la resistencia a la insulina
ES2468040B1 (es) * 2012-11-13 2014-12-26 Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) Microorganismo aislado de leche materna y de heces de un lactante, y su uso como probiótico
CN102960599A (zh) * 2012-11-19 2013-03-13 陕西科技大学 一种含益生元的双歧杆菌微胶囊的制备方法
ITRM20130174A1 (it) * 2013-03-22 2014-09-23 Eurospital S P A Ceppo di lactobacillus e suo uso come probiotico
AU2014304535B2 (en) * 2013-08-09 2017-06-15 Ab-Biotics, S.A. Probiotic for infantile excessive crying
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
WO2015042683A1 (en) * 2013-09-26 2015-04-02 Hassan Firoozmand Biopolymer compositions comprising a plurality of treated single-celled microorganisms
KR102240196B1 (ko) * 2014-03-24 2021-04-15 오츠카 세이야쿠 가부시키가이샤 신규한 락토바실러스 파라카세이 균주
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
RU2605626C2 (ru) * 2015-04-28 2016-12-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский технологический институт пищевой промышленности (университет)" Способ получения бактериального препарата с пробиотической активностью
KR102561989B1 (ko) 2015-05-14 2023-07-31 핀치 테라퓨틱스 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
CN104894021B (zh) * 2015-06-03 2018-02-09 宜兰食品工业股份有限公司 一种副干酪乳杆菌及其应用
CN105176822B (zh) * 2015-10-23 2019-01-11 广州康泽医疗科技有限公司 一种人类肠道益生菌的优化分离方法
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
EP3630190B1 (en) 2017-05-26 2024-02-21 Finch Therapeutics Holdings LLC Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
WO2019136186A2 (en) * 2018-01-03 2019-07-11 Evolve Biosystems, Inc. Method for determining dysbiosis in the intestinal microbiome
TWI705136B (zh) * 2018-01-05 2020-09-21 益福生醫股份有限公司 新穎乳酸菌及其應用
CN108315285A (zh) * 2018-05-08 2018-07-24 西藏高原之宝牦牛乳业股份有限公司 一种副干酪乳杆菌及其制备方法
CN111164201B (zh) * 2018-07-02 2023-09-12 葡萄王生技股份有限公司 用于改善代谢症候群的副干酪乳杆菌gks6、其用途、医药组合物及可食用组合物
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN109134628A (zh) * 2018-09-26 2019-01-04 福建傲农生物科技集团股份有限公司 一种乳酸菌素plnE及其制备方法
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
CN109536415B (zh) * 2018-12-26 2021-12-07 江西仁仁健康产业有限公司 一种鼠李糖乳杆菌及其应用
US20210346434A1 (en) 2019-01-16 2021-11-11 N.V. Nutricia Fermented formula with non-digestible oligosaccharides for use in rotavirus induced infection
US11865151B2 (en) * 2019-02-14 2024-01-09 Gutsybio Inc. Live biotherapeutics for the treatment of carbohydrate disorders
KR102139687B1 (ko) * 2019-05-03 2020-07-30 주식회사 메디오젠 가드네렐라 바기날리스 및 칸디다 알비칸스에 항균 효과를 갖는 질염 치료 또는 개선용 유산균 mg4288
JP7013419B2 (ja) * 2019-08-07 2022-02-15 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
IT201900020422A1 (it) * 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
EP3725167A1 (en) * 2019-11-11 2020-10-21 COREE S.r.l. Synergistic blends of probiotics expressing improved beneficial activity for human host favourably interacting with food, particularly baby food
KR102296286B1 (ko) * 2020-06-16 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 람노서스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2021242057A1 (ko) * 2020-05-28 2021-12-02 주식회사 바이오뱅크힐링 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113817622B (zh) * 2020-06-18 2023-05-26 青岛蔚蓝生物股份有限公司 一株具有减轻致癌物对人体细胞基因毒性作用的长双歧杆菌及其应用
CN111826312B (zh) * 2020-07-10 2022-03-25 江南大学 一株可缓解苯并芘暴露的鼠李糖乳杆菌及其应用
CN111733110B (zh) * 2020-07-17 2021-10-22 佛山市朗芯生物科技有限公司 副干酪乳杆菌及其在制备治疗溃疡性结肠炎药物中的应用
CN114317320B (zh) * 2020-08-24 2022-12-27 汤臣倍健股份有限公司 一种短双歧杆菌207-1及其应用
CN113265351B (zh) * 2021-05-11 2022-05-06 昆明理工大学 一株乳杆菌w8172及其应用
RU2766765C1 (ru) * 2021-05-25 2022-03-15 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ лечения функциональных заболеваний желудочно-кишечного тракта у детей
CN113322216B (zh) * 2021-07-30 2021-11-05 北京量化健康科技有限公司 一种副干酪乳杆菌b111h及其在代谢综合征中的应用
KR102562507B1 (ko) * 2021-12-08 2023-08-02 한국식품연구원 항염증 효과가 뛰어난 신규한 락토바실러스 파라카제이 아종 톨러란스 WiKim0148 및 이의 용도
CN114113023B (zh) * 2021-12-16 2024-04-26 郑州轻工业大学 基于单核增生李斯特菌来源的氮掺杂碳点的制备方法和应用
CN114292779A (zh) * 2021-12-22 2022-04-08 清远西周生物医药科技有限公司 一种副干酪乳杆菌冻干粉、其应用及制备方法
CN114381411B (zh) * 2022-03-23 2022-05-27 山东中科嘉亿生物工程有限公司 乳酸乳球菌jyll-60及其在制备提高免疫力的产品上的应用
CN115998777B (zh) * 2022-10-18 2023-11-17 汤臣倍健股份有限公司 副干酪乳杆菌207-27的用途
CN116731891B (zh) * 2022-12-07 2024-05-07 内蒙古科拓生物有限公司 一株短双歧杆菌b2798及其制备益生菌制剂的用途
CN116855413B (zh) * 2023-07-07 2024-02-09 镇江远森医药科技有限公司 利用鼠李糖乳杆菌YSs069制备调节人体微生态平衡的生物活性物质及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067583A2 (en) * 1999-05-07 2000-11-16 Compagnie Gervais Danone Use of lactic acid bacteria in the preparation of fermented milks for the treatment of depressed immunity levels
EP1415656A1 (en) * 1999-03-11 2004-05-06 Société des Produits Nestlé S.A. Lactobacillus strains capable of preventing diarrhoea caused by rotaviruses
WO2006108824A1 (en) * 2005-04-13 2006-10-19 Nestec S.A. Infant formula with probiotics
WO2007125558A1 (en) * 2006-05-03 2007-11-08 Anidral S.R.L. Symbiotic composition comprising non-digestible polysaccharides and bifidobacteria which metabolize them and its uses
US20080187525A1 (en) * 2007-02-01 2008-08-07 Porubcan Randolph S Formulations Including Digestive Enzymes and Polysorbate Surfactants that Enhance the Colonization of Administered Probiotics Microoganisms
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577904B1 (fr) * 1992-07-06 1997-05-14 Societe Des Produits Nestle S.A. Bactérie lactique
SK283008B6 (sk) * 1997-08-21 2003-01-09 New Zealand Dairy Board Biologicky čistá kultúra Lactobacillus rhamnosus, kompozícia s jej obsahom a jej použitie
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
EP2033529B1 (en) * 2003-10-24 2019-12-11 N.V. Nutricia Synbiotic composition for infants
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
CN1259054C (zh) * 2004-12-27 2006-06-14 孙文基 龙胆苦苷在制备抑制乙型肝炎病毒药物中的应用
US20100166721A1 (en) * 2006-06-09 2010-07-01 Fabiola Masri Probotic compositions and uses thereof
EP1997499A1 (en) * 2007-05-31 2008-12-03 Puleva Biotech, S.A. Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415656A1 (en) * 1999-03-11 2004-05-06 Société des Produits Nestlé S.A. Lactobacillus strains capable of preventing diarrhoea caused by rotaviruses
WO2000067583A2 (en) * 1999-05-07 2000-11-16 Compagnie Gervais Danone Use of lactic acid bacteria in the preparation of fermented milks for the treatment of depressed immunity levels
WO2006108824A1 (en) * 2005-04-13 2006-10-19 Nestec S.A. Infant formula with probiotics
WO2007125558A1 (en) * 2006-05-03 2007-11-08 Anidral S.R.L. Symbiotic composition comprising non-digestible polysaccharides and bifidobacteria which metabolize them and its uses
US20080187525A1 (en) * 2007-02-01 2008-08-07 Porubcan Randolph S Formulations Including Digestive Enzymes and Polysorbate Surfactants that Enhance the Colonization of Administered Probiotics Microoganisms
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARTIN F-P J. ET AL.: "Top-down systems biology integration of conditional prebiotic modulated transgenomic interactions in a humanized microbiome mouse model.", MOLECULAR SYSTEMS BIOLOGY., vol. 4, no. 205, 15 July 2008 (2008-07-15), XP002680209 *
SAAVEDRA J. M. ET AL.: "Use of probiotics in pediatrics: rationale, mechanisms of action and practical aspects.", NUTRITION IN CLINICAL PRACTICE., vol. 22, no. 3, June 2007 (2007-06-01), pages 351 - 365, XP009129949 *
TIMMERMAN H. M. ET AL.: "Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients.", CLINICAL NUTRITION., vol. 26, 2007, pages 450 - 459, XP022159289 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453591C1 (ru) * 2011-04-21 2012-06-20 Общество с ограниченной ответственностью "Бифилюкс" Штамм lactobacillus rhamnosus, используемый для получения продукции, содержащей лактобактерии

Also Published As

Publication number Publication date
ES2532095T3 (es) 2015-03-24
CN104232544B (zh) 2017-04-12
PL2848681T3 (pl) 2017-10-31
WO2010103132A1 (es) 2010-09-16
PL2848681T4 (pl) 2017-10-31
US20130280790A1 (en) 2013-10-24
EP2848681A1 (en) 2015-03-18
EP2848681B1 (en) 2017-04-12
ES2632436T3 (es) 2017-09-13
US8637297B2 (en) 2014-01-28
DK2848681T3 (en) 2017-07-24
PL2407532T3 (pl) 2015-06-30
CN104232545B (zh) 2017-11-21
CN104232544A (zh) 2014-12-24
DK2848682T3 (en) 2017-09-11
US20120076829A1 (en) 2012-03-29
RU2551315C2 (ru) 2015-05-20
EP2407532A2 (en) 2012-01-18
WO2010103140A2 (es) 2010-09-16
CN104232545A (zh) 2014-12-24
RU2011138363A (ru) 2013-04-20
EP2407532A4 (en) 2013-04-10
EP2848682A1 (en) 2015-03-18
EP2848682B1 (en) 2017-05-31
DK2407532T3 (en) 2015-03-09
US20130280789A1 (en) 2013-10-24
EP2407532B1 (en) 2014-12-10
ES2636944T3 (es) 2017-10-10
PL2848682T3 (pl) 2017-12-29
CN102421889A (zh) 2012-04-18
CN102421889B (zh) 2014-10-29

Similar Documents

Publication Publication Date Title
WO2010103140A3 (es) Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
Gupta et al. Probiotics
MXPA04011664A (es) Probioticos y tolerancia oral.
HK1160730A1 (en) Probiotic infant products
CA2893822C (en) Strain of bifidobacterium animalis ssp. animalis
SI3048165T1 (en) NEW SEV BACTERIA BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS CECT 8145 AND ITS APPLICATION FOR INJURY AND / OR PREVENTION OF OVERVIEW OF BODY WEALTH AND BALANCE AND ASSOCIATED DISEASES
KR101487210B1 (ko) 항알레르기용 조성물
PT1359816E (pt) Combinacao de probioticos
MY144315A (en) Beta-galactosidase with transgalactosylating activity
RU2011122453A (ru) Питательная композиция, включающая пробиотики и улучшающая характер сна
NZ593708A (en) Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
WO2011050426A3 (en) New strains of lactic acid bacteria and their combinations producing probiotic preparations
HRP20210995T1 (hr) Uporaba probiotika u liječenju i/ili prevenciji atopičnog dermatitisa
WO2009013709A3 (en) Zinc-enriched biomass, method for the preparation thereof and pro-biotic, cosmetic, dietary and nutraceutic products comprising the same
GB2447006A (en) Galactosidase with alph-galactosyltransferase activity
KR20130141350A (ko) 상피 통과 저항성을 개선하기 위한 프로바이오틱 균주의 용도
Arian et al. Anti-proliferative effects of two new Lactobacillus strains of human origin on Caco-2 cell line
Agarwal et al. Probiotics-A novel approach for health benefits
MX2015010591A (es) Composición de medio de cultivo para favorecer el desarrollo y crecimiento de los microorganismos probióticos lactobacillus plantarum y bifidobacterium animalis.
CZ22460U1 (cs) Rýžový dezert s probiotiky
Lavryk Characteristics of adhesive properties of lactobacillus-clinical isolates and components of biological products
Gomathy Probiotics in Human Diet
RS20100436A2 (en) Indigenous LACTOBACILLUS strains and their use as probiotics
CZ31860U1 (cs) Probiotický jogurtový nápoj z mléka malých přežvýkavců s přídavkem přírodních prebiotik z jakonu
Page RK Agarwal, President IAP 2008, RK Hospital, 5/A, Madhuban, Udaipur 313 001, India. Email:[email protected]

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080020442.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10750390

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010750390

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011138363

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13255842

Country of ref document: US